METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATE RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Supercharged immune cells take on Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase study tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified to better recognize and attack prostate cancer cells while …
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC